What we do FDC Ltd is a research-oriented pharmaceutical company manufacturing and marketing formulations, APIs, and nutraceuticals, leading in ORS, energy drinks, antibiotics, and ophthalmic therapies. |
Founded in 1,940 |
Market share Ranks 23rd in Indian pharma market with 1.09% market share; leading in ORS, antibiotics, and ophthalmic segments. |
Problem solved Develops affordable, specialized formulations addressing dehydration, infections, chronic diseases, and nutritional needs. |
Top clients or who we serve Serves hospitals, clinics, pediatricians, and consumers in India and international markets (B2B and B2C). |
Key management Includes managing director Mohan A. Chandavarkar and executive director Ashok A. Chandavarkar; also notable is independent director Dr. Charuta N Mandke, ophthalmologist. |
Our journey and innovations Founded in 1940; expanded manufacturing with USFDA and EU GMP approvals; launched innovative nutraceuticals and biotech products; expanded global footprint via subsidiaries and joint ventures. |
Where we operate India, USA, UK, South Africa, and markets across Asia Pacific, CIS, Africa, Middle East, LATAM, Australia, and New Zealand. |
Top products or what we offer Key offerings include Electral (ORS), Enerzal (energy drink), Zifi (antibiotics), ophthalmic products, APIs, and nutraceuticals like infant milk substitutes. |
Top brands Electral (#1 ORS brand), Enerzal (fast-growing energy drink), Zifi (leading antibiotic), Calyumm-P (calcium-phosphorus supplement). |
Raw materials needed Raw materials include active pharmaceutical ingredients, excipients, and food-grade ingredients for nutraceutical products. |
Raw materials supplier Suppliers include domestic and international API manufacturers and specialized ingredient providers. |
Recurring vs cyclical contribution Revenue largely recurring from pharmaceuticals and nutraceuticals; some cyclical impacts from regulatory approvals and market expansions. |
Our industry position Leading niche pharmaceutical player in India with growing international presence; strong R&D and manufacturing capabilities. |
Financial highlights FY 2024-25 consolidated revenue ₹2,198.78 crore, net profit ₹266.79 crore, revenue growth ~7%, net profit declined ~12.5% YoY. |
Geographical revenue split India contributes ₹1794.2 crore, others ₹250.18 crore, USA ₹63.75 crore in revenue for FY 2024-25. |
Order book - |
Whats driving growth Growth driven by innovative product launches, regulatory approvals, international market expansion, and rising demand for therapeutics and nutraceuticals. |
Our future plans Focus on US FDA approvals, new generic filings, expanding nutraceutical offerings, and increasing international market penetration. |
Our green promise FDC emphasizes environment-friendly chemical processes, ISO certifications, and sustainable manufacturing practices. |
Our people and values Committed to inclusiveness, employee development, leadership programs, and a safe, ethical working environment. |
Key challenges ahead Regulatory hurdles, competition in global markets, price pressures, and maintaining R&D innovation pace. |
Interesting facts First Indian company to receive US FDA approval for ophthalmic sterile facility; proprietary energy drink featured in Mumbai Marathon; extensive patent portfolio. |
Risks and strategy Mitigation includes robust compliance, diversified product portfolio, focus on niche markets, and continuous R&D investment. |
